• Blog
  • Stem Cell Banking Market Report

    Stem Cell Banking Market Report

    Stem Cell Banking Market Report
    Report code - SR2195 Delivery - 2 Weeks
    Get Free Sample |
    Stem cell banking Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth Op See more...

    Market Insights

    The stem cell banking market was estimated at US$ 4.81 billion in 2021 and is expected to grow at a CAGR of 15.35% during 2022-2028 to reach US$ ~15.56 billion in 2028.

    Stem cells have the capacity to develop into any type of body tissue or organ. In addition to bone marrow, stem cells are also present in foetal tissues, baby teeth, fat, human embryos, hair follicles, muscle, and blood. Cord blood, however, is a reliable source of stem cells. Due to a number of benefits, such as their effectiveness in transplants due to lower risks of immunological rejection during the transfusion, stem cells from cord blood are chosen. The need for stem cell banking is rising as a result of the many ways that stem cells are being used, such as in the treatment of cancer and other disorders. These stem cells are taken from people and stored for potential use.

    Over the forecast period, the global stem cell banking market's expansion is anticipated to be constrained by the high cost of stem cell banking. Because they are pricey, not everyone can afford stem cell preservation treatments. For instance, the private cord blood bank Americord Registry LLC claims that their standard fee ranges from USD 3,299 to USD 6,599 for the collection and 20-year storage of cord blood.

    The use of placental stem cells in clinical settings has increased as it has been demonstrated that these cells have remarkable therapeutic properties in vivo, including anti-oxidant, anti-microbial, anti-inflammatory, pain reduction, hair growth promotion, health improvement, cellular proliferation, tissue regeneration, and wound healing properties. Placental stem cells have the potential to treat illnesses or rare diseases for which there are few effective treatments. These cells, sometimes referred to as the body's "master cells," have the capacity to evolve into the brain, blood bones, and all the organs. These could be used to treat a variety of illnesses and ailments since they have the ability to repair, restore, replace, and regenerate cells. The treatment is very much effective in treating conditions such as Alzheimer's disease.

    Several investments/guidelines in the market have been directed in recent years, which would boost the overall market. Some of them are:

    • The Medical Products Agency granted Xintela approval in July 2022 for a clinical Phase I/IIa research using XSTEM in patients with venous leg ulcers that are challenging to heal. Mesenchymal stem cells that have been quality-assured and integrin 101-selected make up XSTEM, which is created in Xintela's own GMP facility. Twelve patients with venous leg ulcers that are challenging to heal will receive either XSTEM or a placebo in the clinical study, which will be conducted in conjunction with Professor Folke Sjöberg and his team at the University Hospital in Linköping. To assess safety and the effectiveness of the wound healing process, XSTEM/placebo will be administered to the wounds, and the patients will be monitored for 10 weeks. After the summer, the study will begin, and preliminary findings are anticipated by the end of 2022.

    Segment Analysis

    The market is divided based on source, service type, application, and bank type. On the basis of source, the market is further segmented into Placental Stem Cells (PSCs), Human Embryo-Derived Stem Cells (hESCs), Bone Marrow-Derived Stem Cells (BMSCs), Dental Pulp-Derived Stem Cells (DPSCS), Adipose Tissue-Derived Stem Cells (ADSCs), and others.

    On the basis of service type, the market is divided into sample preservation & storage, sample collection & transportation, sample processing, and sample analysis.

    On the basis of application, the market is segmented into personalized banking, research, and clinical. The research segment is further segmented into disease treatment studies, life science research, and drug discovery. Moreover, the clinical segment is further divided into hematopoietic disorders, autoimmune disorders, and others. Researchers from the Harvard Stem Cell Institute have developed a novel therapeutic approach for treating GBMs after surgery utilising stem cells from healthy donors that have been modified to target GBM-specific tumour cells. In preclinical models of GBM, this approach showed remarkable effectiveness, with 100% of mice surviving for more than 90 days.

    The stem cell banking market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America held the largest market share. 

    Key Players

    Stem cell banking is a highly competitive market. To remain competitive in this market, market participants are placing a lot of emphasis on mergers, expansions, and product approvals. Here are a few significant developments:

    • In September 2022, three distinct dose levels of the stem cell product XSTEM will be tested in Australia as part of Xintela's first-in-human trial (Phase I/IIa) for the treatment of knee osteoarthritis. The lowest dose level has now been administered to all patients. Xintela created and produces XSTEM, which is made up of allogeneic (donated) mesenchymal stem cells that have been integrin 101-selected. An injection of XSTEM is given to patients with moderate knee osteoarthritis (grade II–III). Up to 54 individuals at three different dose levels will be studied, and each patient will have an 18-month follow-up with a 6-month efficacy readout. The main objective is to demonstrate the safety of XSTEM while also examining early efficacy indicators such decreased joint cartilage degradation, regrowth of damaged cartilage, and enhanced joint function. Early efficacy results are anticipated in 2023, while initial safety data are anticipated before the end of this year
    • Cryo-Cell International, Inc., the first private cord blood bank in the world to extract and preserve stem cells, and Duke University have collaborated under a licence agreement that was signed in February 2021. The agreement gives Cryo-Cell access to exclusive procedures and legal information on Duke-developed cord blood and cord tissue
    • American CryoStem Corporation, a global licensor, pioneer in autologous cellular processing and therapies, and clinical stage biotechnology business, entered into a contract with BioTherapeutic Labs Corp. (BTL), an FDA-registered manufacturer of umbilical cord tissue, in February 2021. To deliver umbilical cord cells under its previously publicised "CRADA" partnership with the Biomedical Research Laboratory in Bethesda, Maryland, and for upcoming IND applications, CRYO will enhance cell recovery from the umbilical cord. The Agreement calls for BTL to market CRYO's goods and services as well as joint R&D work on protocols that use both BTL's human umbilical cord-derived product lines and ATCell autologous mesenchymal stem cells from CRYO. For usage in its ATCell manufacturing, product development, and the end-to-end CryoStem Platform Technology. the businesses intend to validate and standardise the umbilical cord acellular suspension product.
    • Cryo-Cell International, Inc. and Duke University signed into a patent option agreement in June 2020. The six-month exclusive option contract offers Cryo-Cell the right to choose whether to buy a licence to produce and market goods using Dr. Joanne Kurtzberg's patents.

    The overall competitive landscape has been affected due to these mergers and acquisitions. The following are the major players in the stem cell banking market:

    • BrainStorm Cell Limited
    • Caladrius Biosciences, Inc.
    • Celgene Corporation
    • Cord Blood Registry (CBR) Systems
    • Cordlife Group Limited
    • Cryo-Cell International
    • CryoHoldco 
    • Cryo-Save
    • Global Cord Blood Corporation
    • LifeCell International
    • Regrow Biosciences Pvt. Ltd.
    • Smart Cells International
    • StemCyte
    • ViaCord
    • Vita34 AG

    Research Methodology

    This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both the qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    • Market structure: Overview, industry life cycle analysis, supply chain analysis
    • Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
    • Market trend and forecast analysis
    • Market segment trend and forecast
    • Competitive landscape and dynamics: Market share, product portfolio, product launches, etc.
    • Attractive market segments and associated growth opportunities
    • Emerging trends
    • Strategic growth opportunities for the existing and new players
    • Key success factors

    Frequently Asked Questions (FAQ)

    The stem cell banking market was valued at US$ 4.81 billion in 2021.

    The stem cell banking market valued at US$ ~15.56 billion in 2028.

    The stem cell banking market is growing at a CAGR of 15.35% over the forecast period.

    The major players in the market are BrainStorm Cell Limited, Caladrius Biosciences, Inc., Celgene Corporation, Cord Blood Registry (CBR) Systems, Cordlife Group Limited, Cryo-Cell International, CryoHoldco, Cryo-Save, Global Cord Blood Corporation, LifeCell International, Regrow Biosciences Pvt. Ltd, Smart Cells International, StemCyte, ViaCord, Vita34 AG.

    The stem cell banking market is studied from 2016 - 2028.

    In 2021, North America held the largest market share.